J. Res. Technol. Eng. 5 (3), 2024, 97-110

Journal Of Research Technology & Engineering
www.jrte.org

Exploring the Potential of Artificial Intelligence in Personalized Radiotherapy Planning for Rare Cancers

*W.V.A.S. Lochana

Department of Radiography / Radiotherapy, Faculty of Allied Health Sciences, University of Peradeniya, Sri Lanka
*lochanasachindra123@gmail.com

Received:30 May 2024; Revised: 19 June 2024; Accepted: 28 June 2024; Available online: 10 July 2024

Abstract— The study of artificial intelligence (AI) in personalized radiotherapy planning for rare cancers manifests promising possibilities. Radiotherapy, utilizing high-energy ionizing radiation, has advanced with technological developments such as IMRT, SBRT, and IGRT, upgrading precision and facing challenges such as inherent cancer resistance. Rare cancers, considering 22% of global diagnoses, experience diagnostic difficulties and finite treatment alternatives. AI helps in automating radiotherapy planning, mitigating time and irregularity, and personalizing treatments by patient-specific data. AI utilization in oncology, such as machine learning and neural networks, intensify diagnosis, treatment planning, and prognosis of treatment responses. Future directions incorporate inscribing data insufficiency, interdisciplinary participation, and overcoming technical and ethical challenges to upgrading AI-based medical radiation therapy for rare cancers.
AI's utilization in oncology, incorporating early diagnosis, personalized treatment, and predictive interpretations, signifies considerable developments in clinical outcomes. AI magnify medical imaging, combines various datasets, and aids decision-making procedures. Particularly, AI features motion tracking, automatic segmentation, and dose and outcome prediction, which are critical for rare cancer treatment. For example, AI applications have interpreted effectiveness in anticipating patient outcomes and enhancing radiotherapy plans, adjusting to the unique anatomical characteristics of each patient.

Index Terms— artificial intelligence, personalized radiotherapy, rare cancers, treatment planning

1 Introduction

Radiotherapy, which utilizes high-energy ionizing radiation or radioactive materials, has been a cancer treatment for over a century. Fundamental uncovering of X-rays and radioactivity is associated with the evolution of advanced technology and comprehension. Present Radiotherapy uses several radiation types such as X-rays, gamma rays, electrons, neutrons, and protons delivered externally or internally, targeting cancer cells while sparing normal tissue by fractionating doses. Interactivity of radiation with tissues produces various outcomes (Table 1) [1].

Table 1: Effects of radiations on the irradiated tissues [1]

Effects	Results
Physics	Issue, Transfer and absorption of energy
Biophysics	Ionization and excitation phenomenon
Physical-chemical	Direct alterations of atoms and molecules or indirect damage through the production of free radical
Chemical	The breaking of bonds, polymerization, or depolymerization phenomenon
Biochemical	Molecular alterations
Biochemical –biological	Damage to DNA, RNA, cytoplasm, enzymes
Biological	Aberrations of various cellular components, morpho-functional and metabolic lesions, damage to the genetic material

Rare cancers considered for about 22% of all cancer diagnoses globally, affect a miniature number of individuals, frequently lower than 6 per 100,000 per year. These cancers are strenuous to research attributable to low occurrence and the resultant logistical challenges in supervising trials. The diagnostic procedures for rare cancers are fraught with complexities, often foremost to late or inaccurate diagnoses combined with inadequate clinical proficiency and research interest consequences finite therapeutic choices and impoverished patient results [2]. Technological advancements such as IMRT, IGRT, SBRT and have better accuracy in targeting tumours while reducing impair to healthy tissues, so far numerous cancers show intrinsic or build-up resistance to radiation, and eventually results make complex treatment [3]. Artificial intelligence (AI) is presently used for automatic segmentation and Radiotherapy treatment planning which decreases notably the time and variability involved produce treatment planning. Additionally, AI assists decision-making and acknowledgement by personalizing treatment choices and the selection of optimum therapies depending on patient-specific data. This paper presents an overview of the utilization of probable artificial intelligence in personalized radiotherapy treatment planning for rare cancers. The later part will investigate challenges, limitations, and ethical and legal considerations of using AI in cancer radiotherapy and also focus on future directions, research gaps and some interdisciplinary perspectives to enhance the treatment process which allows the highest performances in personalized rare cancer radiotherapy treatments incorporated with AI.

2 OVERVIEW OF RADIOTHERAPY FOR RARE CANCERS

2.1 Definition of Rare cancers

Rare cancers are described as those with an incidence rate of less than 6 cases per 100,000 people annually. The Joint Action on Rare Cancers (JARC), initiated by the European Union, cooperate with many experts to concentrate on the list of rare cancers originally proposed by the RARECARE project. Rare cancers are categorized into 12 major families to aid clinical significance and organizational purposes (Table 2) [4].

Table 2: Rare cancers: RARECARE ‘families’ with an incidence <6/100 000 [4]

Head and neck	Epithelial tumours of the larynx. Epithelial tumours of the hypopharynx. Epithelial tumours of the nasal cavity and sinuses. Epithelial tumours of the nasopharynx. Epithelial tumours of major salivary glands and salivary gland-type

	tumours. Epithelial tumours of the oropharynx. Epithelial tumours of the oral cavity and lip. Epithelial tumours of the eye and adnexa. Epithelial tumours of the middle ear
Digestive	Epithelial tumours of the small intestine. Epithelial tumours of the anal canal. Epithelial tumours of the gallbladder and extrahepatic biliary duct.
Thoracic	Epithelial tumours of the trachea. Thymomas and thymic carcinomas. Malignant mesothelioma
Female genital	Non-epithelial tumours of the ovary. Epithelial tumours of the vulva and vagina. Trophoblastic tumours of the placenta
Male genital and urogenital	Tumours of the testis and paratestis. Epithelial tumours of the penis. Extragonadal germ cell tumours. Epithelial tumours of the renal pelvis, ureter and urethra
Skin cancers and non-cutaneous melanoma	Mucosal melanoma. Uveal melanoma. Adnexal skin carcinomas. Kaposi sarcoma.
Sarcomas	Soft tissue sarcoma. Bone sarcoma. Gastrointestinal stromal tumours.
Neuroendocrine tumor (NET)	NET gastrointestinal pancreatic. NET lung. NET other sites.
Endocrine organ	Thyroid cancers. Parathyroid cancer. Adrenal cortex cancer. Pituitary gland cancer.
Central nervous system (CNS)	Glial tumours and others. ** Malignant meningioma. Embryonal tumours of CNS.
Pediatric*	Hepatoblastoma. Neuroblastoma and ganglioneuroblastoma. Nephroblastoma. Odontogenic malignant tumours. Olfactory neuroblastoma. Pancreatoblastoma. Pleuropulmonary blastoma. Retinoblastoma

Haematological	Lymphoid malignancies. ** Myelodysplastic syndromes. Myeloproliferative neoplasms (including mastocytosis). Myelodysplastic/myeloproliferative neoplasms. Myeloid/ lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA (platelet-derived growth factor receptor alpha), PDGFRB (platelet-derived growth factor receptor beta), or FGFR1 (fibroblast growth factor receptor 1), or with PCM1-JAK2 Acute myeloid leukemia and related neoplasms *Other neoplasms which mainly, or also, occur in childhood are included under other labels (eg, Ewing's sarcoma and osteosarcoma under bone sarcomas; rhabdomyosarcoma under soft tissue sarcoma; medulloblastoma under embryonal tumour of CNS). **All subgroups (tier 2 entities) within are rare

2.2 Current Radiotherapy methods and their limitations

Present-day radiotherapy techniques have clinically the latest cancer treatment results.3–Dimensional conformal radiotherapy (3D-CRT) and Intensity Modulated Radiotherapy (IMRT) have reinforced tumour targeting and sparing nearby tissues. However, these techniques have obstacles such as excessive gastrointestinal toxicities in some cancers with 3D-CRT and geometric inaccuracies with IMRT. Volumetric modulated arc Therapy (VMRT) offers greater organ sparing but increases low-dose exposure to nearby tissues. Image-guided radiotherapy (IGRT) upgrades accuracy but has issues with target volume delineation and additional radiation from imaging. Stereotactic body radiation therapy (SBRT) delivers high doses to accurate regions but can lead to tissue damage near the target. Particle therapies such as carbon ion and proton therapy anticipate condescending dose distribution and effectiveness for radio-resistant and deep-seated cancers but are costly and logistically demanding. Recently developed perspectives, such as X-ray-induced photodynamic therapy (XPDT) and the utilization of azido-derivatives of 2-deoxy-D-glucose for site-specific DNA damage, are being surveyed to additionally develop radiotherapy productiveness [5].

2.3 Challenges: Specific issues in treating rare cancers

Treating rare cancers introduces a distinctive set of challenges, essentially caused by the low incidence of data, research insufficiency and delayed diagnosis. The insignificant sample sizes in clinical trials frequently usher in low participant engagement, reasoning to trials to be terminated prematurely. The diversity of rare cancers further complicates research, and essential remote studies for each cancer type. Incorrectly diagnosed and late detection are frequent, and limit treatment alternatives. Economically, developing drugs for rare cancers is unattractive to pharmaceutical companies cause of the narrow market, even though initiatives such as the U.S. Food and Drug Administration's (FDA) Orphan Drug Act aim to inscription this. Collaborative international efforts, such as intercontinental clinical trials and databases RARECARE Net, are crucial to overcome these barriers and amplify the evolution of standardized treatment protocols and inventive therapies [4][6].

The low incidence of rare cancers means there is often a lack of high-level evidence and systematised treatment protocols, leading to dependence on case reports and insignificant retrospective analyses. The diversity of rare cancers, integrated with their response to radiotherapy, further complex treatment. For example, mucosal melanomas retaliate well to radiotherapy with decreased local recurrence rates, while the role of radiotherapy in bronchopulmonary neuroendocrine tumours remains uncertain. In addition, advanced radiotherapy techniques, such as stereotactic body radiotherapy (SBRT), convey promise for specific cancers such as hepatobiliary and ovarian malignancies but recommend further research. The finite number of patients and diversified tumour histology in research also restrain definitive conclusions on the effectiveness of radiotherapy over different rare cancers [7].

3 Introduction to Artificial Intelligence in Medicine

3.1 AI Basics: General applications in healthcare

Key applications of Artificial intelligence (AI) in medicine, demonstrating its evolutionary capabilities in different healthcare domains. In research and clinical trials, AI enhances patient selection, cost prediction, data collection and monitoring, thereby modernising these operations. AI impressively intensifies medical imaging and radiology by diagnosing diseases even through the investigations of X-rays, MRIs, and CT scans. The management of electronic health records (EHRs) is also advanced with AI, facilitating superior information capture and study through natural language processing. These algorithms engage in a significant role in diagnosis and clinical decision-making, especially in detecting cancers and other diseases. In surgical utilizations, AI-powered robots such as the Da Vinci surgical system perform procedures with greater accuracy. Personalized medicine is another area where AI excels, customizing therapies according to patient-specific data and genetic information, which magnifies treatment success rates, specifically in cancers. Moreover, AI helps in risk evaluation and prognostication by examining real-time and historical data to recognize high-risk patients and forecast disease progression. virtual health assistants and Telemedicine powered by AI provide assessments and healthcare suggestions, thus enhancing the approach to services also accelerating drug discovery and development by identifying productive drug combinations for complex diseases contributing to patient care and monitoring by tracing symptoms in real-time, assisting healthcare providers in promptly inscribing complications [8].

3.2 AI in Oncology: Overview of AI applications in cancer diagnosis and treatment

AI is revolutionizing oncology by intensifying cancer across different domains, which includes early diagnosis, personalized treatment and research optimization. AI technologies, like machine learning and neural networks, are being used to anticipate patient outcomes, retaliation to therapies, and possible complications (Fig. 1). For example, AI models have demonstrated enhanced precession in risk stratification for colorectal cancer compared to traditional techniques, significantly decreasing false positives and negatives.AI also assists personalized treatment by incorporating data from electronic health records, imaging and genomics [9]. AI utilization for automatic segmentation and planning, remarkably lessen the time and variability necessitated in producing radiotherapy plans. This automation expands with MR-guided systems, where AI helps pseudo-CT generation and motion tracking, consequently reducing patient time and optimizing treatment adaptation on the treatment couch (Fig. 2) [10]. Radio genomics has made significant moves in compassionating the complicated biology of cancer through the combination of advanced genomic data and imaging, substantially supported by AI which advances the analysis and extraction of extensive amounts of data from medical imaging, providing perceptions into tumor diversity and improving prognostic and therapeutic decision- making. AI-based models intensify the accuracy of radio genomic analyses, contributing more definitive survival predictions, treatment responses and recurrence evaluations [11].



Fig.1. Artificial intelligence flywheel
Graphical presentation of the AI and data cycle for fabricating responsible and effective machine learning models for healthcare [9].



Fig. 2. Outline of the modern RT workflow
The superior arm represents cone beam computed tomography (CBCT)-guided RT, while the inferior arm represents MRgRT [10].

4 AI IN RADIOTHERAPY PLANNING

4.1 Machine Learning, Deep Learning and Neural networking

Machine learning(ML), deep learning (DL), and neural networks are progressively essential in oncology, especially in radiotherapy, contributing innovative tools to intensify diagnosis and treatment. Convolutional neural networks (CNNs), a part of DL, modernized the complex radiotherapy workflow, inclusive of tasks such as clinical target volume (CTV) delineation, image fusion, dose distribution prediction, and automatic planning. These implementations enhance diagnosis precision, and objectivity, and decrease clinicians' overload. For example, in image registration, CNN-based methods have dramatically expanded processing speed and precision compared to traditional techniques in attaining significant advancements in tasks such as liver image registration and brain MRI registration. Correspondingly, in image segmentation DL models have shown high precision in automatically delineating organ-at-risk (OAR) and tumours across different cancers, such as nasopharyngeal carcinoma, gliomas, and brain tumours, frequently surpassing traditional methods [12][13].

4.2 Examples of AI applications in radiotherapy for common cancers

In this topic, AI utilization in radiotherapy for common cancers, especially non-small-cell lung cancer (NSCLC) exhibits outstanding potential in enhancing clinical outcomes and efficiency. The research involved 2208 patients from various international datasets, emphasizing robust external radiotherapy. Results of the study conveyed that AI models not only enhanced segmentation precision and consistency but also decreased segmentation time by 65% and interobserver variability by 32%, despite geometric deviations. AI-assisted segmentations sustained equivalent radiation dose coverage compared to expert segmentations. These discoveries emphasize AI's potential to modernise radiotherapy planning and upgrade clinical usefulness in treating NSCLC [14]. The applications of AI utilization in radiotherapy for lung cancer, magnify the efficiency and precision of reading low-dose computed tomography(LDCT) and chest X-rays, decreasing radiologists 'workload and increasing the accuracy of nodule identification [15]. The latest AI utilization in prostate cancer has engaged in automating clinical workflows, combining multi-domain data for decision-making and developing diagnostics and predictive biomarkers [16].

5 SPECIFIC APPLICATIONS OF AI IN RADIOTHERAPY FOR RARE CANCERS

5.1 How AI handles limited and diverse data sets

AI plays a key role in handling various and limited datasets in rare cancers, demonstrated by its potential to merge diverse data types and sizes, thereby intensifying diagnostic precision and treatment strategies [17]. A structure called MOSAIC, engaging AI for classification, multimodal analysis, and personalized prognostic evaluation in rare cancers, was evolved and substantiated on myelodysplastic syndrome (MDS) a rare hematologic cancer with genomic and clinical diversities, exhibiting condescending patient stratification through Uniform Manifold Approximation and Projection + Hierarchical Density-Based Spatial Clustering of Applications with Noise (UMAP + HDBSCAN) clustering and AI-based survival prognostication techniques, inclusive of Gradient Boosting, which Outperformed traditional perspectives, with Shapley Additive Explanations Approach (SHAP) analysis magnifying model interpretability and integrated learning were used to enhance performance and interpretation of clinical techniques (Fig. 3) [18]. The literature review focuses attention on the outstanding capabilities of AI enhancing the diagnosis, treatment and prognosis of rare diseases by leveraging machine learning (ML) algorithms to examine multiplex and high-dimensional data. Examples include using IBM Watson® for amyotrophic lateral sclerosis with an area under the curve (AUC) of 0.935, Mean reciprocal Rank (MRR) of 0.231 and artificial neural networks (ANN) for Gaucher disease attaining Hits@10 of 0.454, and random forests (RF) for Duchenne muscular dystrophy with an accuracy of 72% [19].



Fig. 3. Overview of the MOSAIC framework applied to training and validation cohorts [18]

5.2 Personalization of radiotherapy plans using AI

In recent years, with the personalization of AI utilizations applicable in medical radiation therapy for rare cancers, AI-driven techniques such as automated treatment planning (ATP) have evolved to tailor radiotherapy plans to the particular requirements of individual patients, as a result intensifying treatment effectiveness and coherence. For instance, deep convolutional neural networks (CNNs) have been extensively considered for their capability to forecast dose distributions with high validity, acknowledging more accurate treatment plans that contemplate the distinctive anatomical characteristics of each patient. Moreover, generative adversarial networks (GANs) have been exploited to revitalise decision-making approaches in treatment planning, allocating to optimize dose distributions based on previously acquired data rather than entirely anticipating trial and error mechanisms. Another innovative perspective involves the utilization of reinforcement learning. Which mimics human reasoning by making consecutive recommendations that can have long-term consequences on patient outcomes. In addition, knowledge-based planning modules, thus those that utilize support vector regression (SVR), have been engaged to prognosticate optimal planning frameworks by learning from past successful treatment plans [20]. These AI-driven models not only refine the accuracy and steadiness of radiotherapy objectives but also decrease the time and effort essential for human planners, permitting further personalized and successful management of rare cancers.

5.3 Review of specific instances where AI has been applied to rare cancers

AI has been manipulated to initiate radiomics models that forecast treatment responses and convey individualized radiotherapy intentions. Utilized CT-based radiomics to discriminate between atypical serous cystadenomas and pancreatic mucinous cystic neoplasm, authorizing personalized treatment tactics [21]. Another representative case, is the logistic regression models to prognosticating thyroid cartilage invasion in hypopharyngeal squamous cell carcinoma and laryngeal carcinoma, facilitating additional accurate surgical radiotherapy interventions [22]. Implementation of deep learning (DL) in automatic segmentation for radiotherapy in rare cancer examines 807 papers across numerous cancer sites and diagnostic modalities. DL, especially operating convolutional neural networks (CNNs), has been extremely productive in automating the segmentation of tumours and organs, necessary for reliable radiotherapy planning. significance applications incorporate brain tumour segmentation, prostate gland and surrounding organs, lung tumours, and head and neck structures [23].

AI-based movement observations and tracking in radiotherapy for rare cancers considerably amplified the precision and productiveness of treatment by addressing intra-fractional movements, which are the motions of tumours throughout radiation delivery. Techniques such as Volumetric modulated arc therapy (VMRT) and Stereotactic body radiotherapy (SBRT) are especially enhanced by AI, which uses deep learning (DL) and machine learning (ML) algorithms to forecast and track tumour motions in real-time. For example, Artificial neural networks (ANNs) have been engaged to prognosticate lung tumour locations throughout treatment, capitulating additional accurate outcomes than conventional practices. Also, models such as the YOLU (You Only Look Once) convolutional neural network have been utilized to distinguish fiducial markers in X-ray images with elevated accuracy [24].

AI excels at understanding complex patterns in medical images, converting image interpretation from subjective to quantifiable and reproducible tasks. For instance, AI-based computer-aided detection (CADe) tools assist decrease observational inaccuracies, enhancing the sensitivity of radiologists in distinguishing abnormalities such as missed cancers in low-dose CT scans and microcalcifications in mammograms [25]. AI models combining tumour and nodal imaging characteristics are utilized to prognosticate distant metastasis in Oropharyngeal region cancers. An additional application is the prediction of radiation-affected parotid shrinkage and toxicity using CT radiomics and fuzzy classification. Moreover, MRI-based AI models aid adapt radiotherapy to reduce side effects such as xerostomia in head and neck cancer patients [26].

In the diagnosis of rare diseases, AI plays a significant role by upgrading image processing, genetic analysis, and clinical decision support systems. Machine learning algorithms help in recognizing rare disease subtypes and predicting disease progression based on phenotypic and genetic data. Implements such as PheanlX and Xrare use AI to categorize genetic variants associated with rare diseases, facilitating faster and more precise diagnosis compared to traditional techniques [27][28].

6 FUTURE DIRECTIONS

6.1 Research gaps

Despite the rapid advancement of AI in healthcare, there are significant gaps in its utilization particularly tailored to rare cancer radiation therapy. One major gap lies in the insufficiency of robust data collections for rare cancers, which be a hindrance to the development and acceptance of AI models [29]. The majority of AI algorithms in radiotherapy depend on data from common cancers, placing a limit on their effectiveness in rare cancer cases [30]. Additionally, the generalizability of AI models across various patient populations and treatment settings persists inadequately exploded, constituting challenges in their clinical usefulness [31]. Addressing these gaps prerequisites collaborative efforts among clinicians, researchers, and data scientists to collect and organize comprehensive datasets and legitimize AI algorithms in diversified clinical scenarios.

6.2 Emerging technologies

Recent advancements in AI technologies hold promise for amplifying the accuracy and efficacy of radiation therapy for rare cancers [32]. Machine learning algorithms, especially deep learning models, have demonstrated superior performance in image segmentation, treatment planning, and outcome prediction [33]. For example, AI-based processes have shown potential in automating target delineation in radiotherapy planning, thereby lessening inter-observer variability and magnifying treatment accuracy. Additionally, AI-powered adaptive radiotherapy systems can dynamically rearrange treatment parameters depending on real-time patient data, improving therapeutic outcomes while reducing radiation exposure to healthy tissues [34]. These advancements emphasize the transformative influence of AI in personalizing treatment approaches for rare cancer patients.

6.3 Interdisciplinary approaches

The combination of AI in rare cancer radiotherapy essentially requires interdisciplinary collaboration across computer science, medical physics, oncology, and biomedical engineering. Multidisciplinary teams permit the evolution of AI-driven tools that cater to the unique challenges constituted by rare cancers, such as insufficient treatment guidelines and variability in disease presentation. By incorporating proficiency in clinical oncology with computational methods, researchers can pioneer novel AI solutions that make alterations to developing clinical requirements and patient-specific characteristics. Interdisciplinary approaches not only foster innovation but also ensure the ethical deployment of AI technologies in healthcare settings [35].

6.4 Technical Challenges

Despite its potential, the combination of AI in rare cancer radiation therapy is fraught with technical challenges. One significant difficulty is the interpretability of AI algorithms especially in complex decision-making tasks including treatment planning. Clinicians are essential to transparent AI models that dispense extensive rationales for their recommendations and make certain trust and clinical acceptance. Furthermore, the validity of AI algorithms to variations in treatment protocols, imaging quality, and patient demographics remains a critical concern. Standardizing AI application frameworks and benchmarking methodologies are important to alleviate variability and amplify the reliability of AI-driven radiotherapy techniques [36].

6.5 Ethical and Legal Considerations

The ethical suggestions of AI in rare cancer radiotherapy enclose a spectrum of issues, incorporating patient privacy, concurrence for AI-driven interventions, and algorithmic bias. AI algorithms instructed on imbalanced datasets may preserve discrepancies in treatment outcomes between underrepresented patient groups. Additionally, the liability correlated with AI-generated treatment plans elevates legal apprehensions concerning accountability and professional misconduct. Regulatory frameworks must make alternations to accommodate AI technologies, ensuring adherence to ethical standards and safeguarding patient well-being. Establishing guidelines for AI applications in clinical practice requires cooperation among healthcare providers, policymakers, and technology developers to stabilize innovation with ethical considerations [37].

2.4 Implementation Barriers

The movement of AI research into clinical implementation faces application barriers, embracing financial limitations, infrastructure requirements, and resistance to switching between healthcare professionals. Limited institutional contribution for integrating AI systems into existing radiotherapy workflows hinders adoption rates and versatility. Furthermore, the requirement for specialized training in AI between medical physicists and radiation oncologists emphasizes the significance of educational initiatives and professional development programs [38]. Deal with these barricades demands a concerted attempt to invest in encouraging policies, infrastructure customizations, and stakeholder commitment strategies that accelerate the absolute combination of AI in rare cancer radiotherapy [39].

8 Conclusion

The exploration of artificial intelligence (AI) in personalized radiotherapy planning for rare cancers discloses outstanding potential to intensify treatment effectiveness and patient outcomes. Radiotherapy has long been a keystone in cancer treatment, developing with technological improvements to upgrade accuracy and decrease impairment to healthy tissues. Nevertheless, rare cancers, which represent about 22% of global cancer diagnoses, present unique challenges due to their low incidence, diagnostic complexities, and narrow research focus.

Current radiotherapy techniques such as IMRT, IGRT, and SBRT, though complicated, face limitations such as geometric errors, logistical challenges, and higher toxicities, significantly for rare cancers. AI materializes as a transformative tool, contributing automation in segmentation and planning, thereby decreasing time and variability. The AI-driven technique enhances the accuracy of radiotherapy plans, leveraging machine learning (ML) and deep learning (DL) to intensify diagnostic precision and treatment personalization.

AI's implementations in oncology, inclusive of early diagnosis, personalized treatment, and prognosticative analytics, demonstrate substantial advancements in clinical outcomes. AI magnifies medical imaging, integrates various datasets, and aids decision-making processes. Particularly, AI makes possible automatic segmentation, motion tracking, dose prediction, and outcome prognostication, significant for rare cancer treatment. For example, AI techniques have shown effectiveness in predicting patient outcomes and advancing radiotherapy plans, adjusting to the unique anatomical characteristics of a particular patient.

Despite these improvements, challenges endure in the implementation of AI for rare cancers. The insufficiency of robust datasets, the requirement for interdisciplinary collaboration, and the necessity for transparent AI algorithms are significant obstacles. Addressing these gaps necessitates shared efforts between researchers, clinicians, and data scientists to curate comprehensive datasets and authenticate AI models across various clinical scenarios.

Emerging technologies such as AI-powered adaptive radiotherapy systems and automated treatment planning hold a guarantee for increasing treatment accuracy and minimizing radiation exposure to healthy tissues. Nevertheless, technical challenges such as algorithm interpretability, irregularities in imaging quality, and standardization of AI substructure are required to be addressed to make certain definitive and trustworthy AI-driven solutions.

Ethical and legal contemplations are paramount in the deployment of AI in healthcare. Matters such as consent for AI interventions, patient privacy, and algorithmic bias must be conscientiously managed. Regulatory frameworks should be modified to accommodate AI technologies and make certain ethical standards and patient safety.

Implementation barriers, which include infrastructure requirements, financial constraints, and resistance to change between healthcare professionals, be a hindrance to the widespread assumption of AI in radiotherapy. Overcoming these barriers demands expenditures in encouraging policies, infrastructure improvements, and educational resourcefulness for healthcare providers.

In conclusion, AI detains transformative capabilities in personalized radiotherapy planning for rare cancers and provides significant advancements in treatment accuracy and patient outcomes. Collaborative, interdisciplinary attempts and strong ethical guidelines are essential to fully harness AI's capabilities and combine them into clinical practice successfully.

References

[1] S. Gianfaldoni, R. Gianfaldoni, U. Wollina, J. Lotti, G. Tchernev, and T. Lotti, "An Overview on Radiotherapy : From Its History to Its Current Applications in Dermatology," vol. 5, no. 4, pp. 521–525, 2017.

[2] R. Pillai and K. Jayasree, "Rare cancers: Challenges & issues," *Indian J. Med. Res.*, vol. 145, no. 1, p. 17, Jan. 2017, doi: 10.4103/ijmr.IJMR_915_14.

[3] H. H. W. Chen and M. T. Kuo, "Improving radiotherapy in cancer treatment : Promises and challenges," vol. 8, no. 37, pp. 62742–62758, 2017.

[4] P. G. Casali and A. Trama, "Rationale of the rare cancer list : a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU)," *ESMO Open*, vol. 5, no. 2, p. e000666, 2020, doi: 10.1136/esmoopen-2019-000666.

[5] C. Management, "Technological Advancements in External Beam Radiation Therapy (EBRT): An Indispensable Tool for Cancer Treatment," no. April, pp. 1421–1429, 2022.

[6] G. Christyani, M. Carswell, S. Qin, and W. Kim, "An Overview of Advances in Rare Cancer Diagnosis and Treatment," 2024.

[7] A. Fiorentino *et al.*, "Critical Reviews in Oncology / Hematology Radiation treatment for adult rare cancers : Oldest and newest indication," *Crit. Rev. Oncol. / Hematol.*, vol. 159, no. December 2020, p. 103228, 2021, doi: 10.1016/j.critrevonc.2021.103228.

[8] P. Perspectives, "Transformative Potential of AI in Healthcare : Definitions , Applications , and Navigating the Ethical Landscape and Public Perspectives," 2024.

[9] E. Farina *et al.*, "An Overview of Artificial Intelligence in Oncology An overview of artificial intelligence in oncology," 2022, doi: 10.2144/fsoa-2021-0074.

[10] G. Landry, C. Kurz, and A. Traverso, "The role of artificial intelligence in radiotherapy clinical practice," *BJR|Open*, vol. 5, no. 1, p. 20230030, Nov. 2023, doi: 10.1259/bjro.20230030.

[11] S. Saxena *et al.*, "Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine," *Cancers (Basel).*, vol. 14, no. 12, 2022, doi: 10.3390/cancers14122860.

[12] D. Huang *et al.*, "The Application and Development of Deep Learning in Radiotherapy : A Systematic

Review," vol. 20, pp. 1–8, 2021, doi: 10.1177/15330338211016386.
[13] M. Field, N. Hardcastle, M. Jameson, N. Aherne, and L. Holloway, "Machine learning applications in radiation oncology," *Phys. Imaging Radiat. Oncol.*, vol. 19, no. May, pp. 13–24, 2021, doi: 10.1016/j.phro.2021.05.007.
[14] A. Hosny *et al.*, "Articles Clinical validation of deep learning algorithms for radiotherapy targeting of non-small-cell lung cancer : an observational study," *Lancet Digit. Heal.*, vol. 4, no. 9, pp. e657–e666, 2022, doi: 10.1016/S2589-7500(22)00129-7.
[15] H. Chiu, H. Chao, and Y. Chen, "Application of Artificial Intelligence in Lung Cancer," 2022.
[16] A. Baydoun *et al.*, "Artificial intelligence applications in prostate cancer.," *Prostate Cancer Prostatic Dis.*, vol. 27, no. 1, pp. 37–45, Mar. 2024, doi: 10.1038/s41391-023-00684-0.
[17] D. Cirillo, I. Núñez-Carpintero, and A. Valencia, "Artificial intelligence in cancer research: learning at different levels of data granularity," *Mol. Oncol.*, vol. 15, no. 4, pp. 817–829, Apr. 2021, doi: https://doi.org/10.1002/1878-0261.12920.
[18] S. D. Amico, L. D. Olio, C. Rollo, P. Alonso, and I. Prada-luengo, "MOSAIC : An Arti fi cial Intelligence – Based Framework for Multimodal Analysis , Classi fi cation , and Personalized Prognostic Assessment in Rare Cancers," pp. 1–13, doi: 10.1200/CCI.24.00008.
[19] A. Visibelli, B. Roncaglia, and O. Spiga, "The Impact of Artificial Intelligence in the Odyssey of Rare Diseases," pp. 1–23, 2023.
[20] C. Wang, X. Zhu, J. C. Hong, and D. Zheng, "Artificial Intelligence in Radiotherapy Treatment Planning : Present and Future," vol. 18, pp. 1–11, 2019, doi: 10.1177/1533033819873922.
[21] T. Xie, X. Wang, Z. Zhang, and Z. Zhou, "CT-Based Radiomics Analysis for Preoperative Diagnosis of Pancreatic Mucinous Cystic Neoplasm and Atypical Serous Cystadenomas.," *Front. Oncol.*, vol. 11, p. 621520, 2021, doi: 10.3389/fonc.2021.621520.
[22] R. Guo *et al.*, "CT-based radiomics features in the prediction of thyroid cartilage invasion from laryngeal and hypopharyngeal squamous cell carcinoma.," *Cancer imaging Off. Publ. Int. Cancer Imaging Soc.*, vol. 20, no. 1, p. 81, Nov. 2020, doi: 10.1186/s40644-020-00359-2.
[23] L. J. Isaksson *et al.*, "Automatic Segmentation with Deep Learning in Radiotherapy," 2023.
[24] E. Salari, J. Wang, J. Wynne, C. Chang, and X. Yang, "Artificial Intelligence-based Motion Tracking in Cancer Radiotherapy : A Review," pp. 1–38.
[25] W. L. Bi *et al.*, "Artificial Intelligence in Cancer Imaging : Clinical Challenges and Applications," vol. 0, no. 0, pp. 1–31, 2019, doi: 10.3322/caac.21552.
[26] C. Bang, G. Bernard, W. T. Le, A. Lalonde, S. Kadoury, and H. Bahig, "Clinical and Translational Radiation Oncology Artificial intelligence to predict outcomes of head and neck radiotherapy," *Clin. Transl. Radiat. Oncol.*, vol. 39, no. January, p. 100590, 2023, doi: 10.1016/j.ctro.2023.100590.
[27] M. Wojtara and H. Singh, "Artificial intelligence in rare disease diagnosis and treatment," no. May, pp. 2106–2111, 2023, doi: 10.1111/cts.13619.
[28] L. Angeles, "Arti fi cial intelligence in radiotherapy : a technological review," 2020.
[29] D. Donadio and S. F. Terry, "The Application of Artificial Intelligence in the Diagnosis of Cancer and Rare Genetic Diseases," *Genet. Test. Mol. Biomarkers*, vol. 27, no. 7, pp. 203–204, Jul. 2023, doi: 10.1089/gtmb.2023.29074.persp.
[30] B. Zhang, H. Shi, and H. Wang, "Machine Learning and AI in Cancer Prognosis , Prediction , and Treatment Selection : A Critical Approach," no. June, pp. 1779–1791, 2023.
[31] K. A. Wahid *et al.*, "Arti fi cial Intelligence for Radiation Oncology Applications Using Public Datasets," *Semin. Radiat. Oncol.*, vol. 32, no. 4, pp. 400–414, 2022, doi: 10.1016/j.semradonc.2022.06.009.
[32] J. Liao *et al.*, "Artificial intelligence assists precision medicine in cancer treatment," *Front. Oncol.*, vol. 12, 2023, [Online]. Available: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.998222
[33] K. Bera, N. Braman, A. Gupta, V. Velcheti, and A. Madabhushi, "Predicting cancer outcomes with radiomics and artificial intelligence in radiology," *Nat. Rev. Clin. Oncol.*, vol. 19, no. 2, pp. 132–146, 2022, doi: 10.1038/s41571-021-00560-7.
[34] A. M. Sebastian and D. Peter, "Artificial Intelligence in Cancer Research : Trends , Challenges and Future Directions," 2022.
[35] R. Article, "Advancements in Oncology with Artificial Intelligence—A Review Article," pp. 1–19, 2022.
[36] W. L. Bi *et al.*, "Artificial intelligence in cancer imaging: Clinical challenges and applications," *CA. Cancer J. Clin.*, vol. 69, no. 2, pp. 127–157, Mar. 2019, doi: https://doi.org/10.3322/caac.21552.
[37] M. Goisauf and M. Cano Abadía, "Ethics of AI in Radiology: A Review of Ethical and Societal Implications ," *Frontiers in Big Data* , vol. 5. 2022. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fdata.2022.850383
[38] E. Naab *et al.*, "Physica Medica Africa ' s readiness for artificial intelligence in clinical radiotherapy delivery :

Medical physicists to lead the way," *Phys. Medica*, vol. 113, no. August, p. 102653, 2023, doi: 10.1016/j.ejmp.2023.102653.

[39] R. Thompson *et al.*, "Artificial intelligence in radiation oncology: A specialty-wide disruptive transformation?," *Radiother. Oncol.*, vol. 129, Jun. 2018, doi: 10.1016/j.radonc.2018.05.030.